Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2W0LG
|
|||
| Drug Name |
PF-06835375
|
|||
| Indication | Immune thrombocytopenic purpura [ICD-11: 3B64.13; ICD-10: D69; ICD-9: 287.31] | Phase 2 | [1] | |
| Systemic lupus erythematosus [ICD-11: 4A40.0; ICD-9: 710] | Phase 1 | [2] | ||
| Company |
Pfzer
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | C-X-C chemokine receptor type 5 (CXCR5) | Target Info | Inhibitor | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05070845) AN INTERVENTIONAL PHASE 2, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06835375 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PRIMARY IMMUNE THROMBOCYTOPENIA. U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT03334851) A PHASE 1, RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, SPONSOR OPEN, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.